Last updated on February 2018

Open Label Study to Assess Safety PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis


Brief description of study

This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis. Eligible subjects will be enrolled and randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily for 8 weeks.

Clinical Study Identifier: NCT02768974

Contact Investigators or Research Sites near you

Start Over

Alexander Fich, MD, Prof.

Soroka University Hospital
Be'er-Sheva, Israel
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.